BMY Bristol-Myers Squibb Company Common Stock
$67,40
Prezzo · Ago 25, 2026
Fondamentali al Lug 30, 2026
Intervallo 52 sett.
$43–$69
95% of range
Rating Analisti
HOLD
35 analysts
Prezzo Obiettivo
$66
P/E (TTM)
15.6
ROE
40.5%
Margine di Profitto Netto
14.6%
Informazioni su Bristol-Myers Squibb Company Common Stock Panoramica della società da Wikipedia
Bristol-Myers Squibb, è una delle principali aziende farmaceutiche a livello mondiale. La società ha sede a New York ed è quotata al NYSE.
Leggi di più
Bristol-Myers Squibb, è una delle principali aziende farmaceutiche a livello mondiale. La società ha sede a New York ed è quotata al NYSE.
Produce farmaci da prescrizione in diverse aree terapeutiche, tra cui il cancro, l'HIV/AIDS, le malattie cardiovascolari, il diabete, l'epatite, l'artrite reumatoide e i disturbi psichiatrici.
Storia
La società ha raggiunto l'attuale assetto nel 1989, quando è stata attuata la fusione tra due aziende storiche del settore farmaceutico:
la Bristol-Myers Company, fondata nel 1887 da William McLaren Bristol e John Ripley Myers allo scopo di rilevare una preesistente società in stato fallimentare, la Clinton Pharmaceutical Company;
la Squibb Corporation, fondata nel 1858 da Edward Robinson Squibb.
La fusione è stata effettuata attraverso l'incorporazione della Squibb nella Bristol-Myers.
Nel luglio 2009 si espande negli anticorpi acquisendo per 2,4 miliardi di dollari Medarex. Nell'ottobre 2010 acquisisce Zymogenetics (epatite C e cancro). Nello stesso anno Lamberto Andreotti è nominato CEO dopo aver ricoperto il ruolo di responsabile delle operazioni farmaceutiche in tutto il mondo. Nel gennaio 2012 la società rileva per 2,5 miliardi di dollari in contanti la Inbitex per rafforzare la sua posizione nel settore dei farmaci contro l'epatite C e così competere con Gilead/Pharmasset. L'accordo è completato in soli due mesi grazie al premio del 126% sull'ultimo prezzo di negoziazione. Sempre nello stesso anno, in giugno, acquista Amylin Pharmaceuticals Inc per 5,3 miliardi di dollari, anche questi in contanti. AstraZeneca, che già collabora in diversi trattamenti per il diabete con BMS, pagherà 3,4 miliardi di dollari in contanti per i diritti a sviluppare i prodotti Amylin.
Con una capitalizzazione di mercato di 87 miliardi di dollari e un apprezzamento delle azioni del 61,4%, Bristol-Myers Squibb è classificata come la migliore azienda farmaceutica del 2013 da Forbes Magazine. Sempre nel 2013 la società paga una multa di 18 milioni di dollari per aver negli anni passati evaso il fisco.
Il 3 gennaio 2019 la società ha annunciato l'acquisto della società biofarmaceutica Celgene, con sede nel New Jersey, per un valore di 74 miliardi di dollari, parte in azioni (ultima seduta di BMS a 52,43 dollari) e parte cash (50 dollari per ciascun titolo). Con la transazione, tra le più grandi nel settore farmaceutico, nasce un leader nei trattamenti contro il cancro e le malattie immunologiche. Gli azionisti Bristol-Myers Squibb avranno circa il 69% della nuova società, quelli di Celgene circa il 31%.
Produzione
La produzione del gruppo Bristol-Myers Squibb si articola in tre grandi divisioni:
la Divisione farmaceutica, di gran lunga la più importante e che rappresenta oltre il 70% del fatturato globale del gruppo, specializzata nella produzione di farmaci diversi, in particolare per i settori:
Antibiotico e antinfettivo
Antivirale
Cardiologico
Terapia del dolore
Neuroscienze
Oncologia
la Divisione cibi dietetici, in particolare prodotti per l'alimentazione dei bambini
la Divisione articoli sanitari diversi.
Dati economici
Nel 2017 il gruppo ha toccato i 20,788 miliardi di dollari rispetto ai 19,4 miliardi del 2016 con un utile di 975 milioni. La capitalizzazione a Wall Street è nel 2016 di oltre 106 miliardi di dollari.
Struttura
I siti primari di R & S di BMS si trovano a Lawrence, nel New Jersey (precedentemente Squibb, vicino a Princeton) e a Wallingford, nel Connecticut (ex Bristol-Myers); con altri siti a East Syracuse, New York; Princeton Pike, Hopewell township e New Brunswick, nel New Jersey, e a Swords, in Irlanda; Braine-l'Alleud, Belgio; Tokyo, Giappone; Bangalore, India.
In Italia il gruppo è rappresentato dalla Bristol-Myers Squibb s.r.l., attivo dal 1946, con un ufficio di rappresentanza a Roma. Sono 17 le nuove molecole (di cui 10 biotech) allo studio della filiale italiana che collabora con Ieo e Istituto dei tumori di Milano. Lo storico stabilimento di Anagni (FR) è stato ceduto nel 2020 a Catalent (Blackstone Group, che poi l'ha ceduta a Novo Nordisk), ma continua a produrre farmaci BMS.
Suoi prodotti
Entecavir (Baraclude)
Apixaban (Eliquis)
Warfarin (Coumadin)
Abatacept (Orencia)
Dasatinib (Sprycel)
Atazanavir (Reyataz)
Daclatasvir (Daklinza)
Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Elotuzumab (Empliciti)
Fonte: Wikipedia, CC BY-SA 4.0 · Vedi su Wikipedia ↗
BMY Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$67.40
Capitalizzazione di Mercato
—
P/E (TTM)
15.6
EPS (TTM)
$3.46
Ricavi (TTM)
$48.19B
Rendimento div.
—
ROE
40.5%
D/E Debito/Patrimonio
2.5
Intervallo 52 sett.
$43 – $69
BMY Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$48.19B
2019-12-31
→
2025-12-31
EPS
$3.46
2019-12-31
→
2025-12-31
Flusso di cassa libero
$12.85B
2019-12-31
→
2025-12-31
Margini
14.6%
2019-12-31
→
2020-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
BMY
Mediana dei peer
P/E (TTM)
15.6
32.1
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
BMY
Mediana dei peer
Net Profit Margin (Margine di Profitto Netto)
14.6%
13.0%
ROA
7.7%
6.4%
ROE
40.5%
15.1%
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
BMY
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
2.5
—
Current Ratio (Rapporto corrente)
1.3
1.6
Quick Ratio
0.8
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
BMY
Mediana dei peer
Revenue YoY (Ricavi YoY)
-0.22%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
1.5%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
2.5%
—
EPS YoY
30.9%
—
Net Income YoY (Utile Netto YoY)
26.8%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
BMY
Mediana dei peer
Payout Ratio (Rapporto di Distribuzione Utili)
71.5%
—
Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y
Dividend Yield
—
Rapporto di Distribuzione Utili
71.5%
CAGR Dividendi 5Y
—
| Data ex-dividendo | Importo |
|---|---|
| 02 Luglio 2026 | $0,6300 |
| 02 Aprile 2026 | $0,6300 |
| 02 Gennaio 2026 | $0,6300 |
| 03 Ottobre 2025 | $0,6200 |
| 03 Luglio 2025 | $0,6200 |
| 04 Aprile 2025 | $0,6200 |
| 03 Gennaio 2025 | $0,6200 |
| 04 Ottobre 2024 | $0,6000 |
| 05 Luglio 2024 | $0,6000 |
| 04 Aprile 2024 | $0,6000 |
| 04 Gennaio 2024 | $0,6000 |
| 05 Ottobre 2023 | $0,5700 |
| 06 Luglio 2023 | $0,5700 |
| 06 Aprile 2023 | $0,5700 |
| 05 Gennaio 2023 | $0,5700 |
| 06 Ottobre 2022 | $0,5400 |
| 30 Giugno 2022 | $0,5400 |
| 31 Marzo 2022 | $0,5400 |
| 06 Gennaio 2022 | $0,5400 |
| 30 Settembre 2021 | $0,4900 |
BMY Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
35 analisti
- Acquisto forte 6 17,1%
- Compra 8 22,9%
- Mantieni 19 54,3%
- Vendi 2 5,7%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
24 analisti · 2026-08-24
Mediana
$68.00
Ora
$67.40
Basso
$40.00
Alto
$80.00
Target mediano
$68.00
+0,9%
Target medio
$66.21
-1,8%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.25%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $2.04 | $1.60 | 0.44% |
| 31 Marzo 2026 | $1.58 | $1.43 | 0.15% |
| 31 Dicembre 2025 | $1.26 | $1.13 | 0.13% |
| 30 Settembre 2025 | $1.63 | $1.52 | 0.11% |
| 30 Giugno 2025 | $1.46 | $1.08 | 0.38% |
| 31 Marzo 2025 | $1.80 | $1.51 | 0.29% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
Stato Patrimoniale 31
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
Flusso di cassa 19
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
Redditività 6
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
Tassi di Crescita 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 6
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
Stato Patrimoniale 29
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
Flusso di cassa 19
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
Redditività 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
Valutazione (TTM) 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Utile netto | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| EPS Diluito | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| Rapporto corrente | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
Ultime notizie Notizie recenti che menzionano questa società
- La presunta megaprogetto da $400 miliardi tra AstraZeneca e Bristol Myers Squibb è un successo assicurato o un disastro imminente?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 2.785 filer · $58.1B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 159 (-159 vs trimestre precedente) | 154 (+18 vs trimestre precedente) | 1.006 (-29 vs trimestre precedente) | 987 (+89 vs trimestre precedente) | +55.3M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7.682.927.263 | 133.337.856 | 13,22% | Azioni |
| STATE STREET CORP | $5.900.803.123 | 102.408.940 | 10,15% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.894.809.793 | 67.594.755 | 6,70% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $2.858.273.235 | 49.750.183 | 4,92% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.700.823.125 | 46.873.015 | 4,65% | Azioni |
| NORGES BANK | $2.124.256.834 | 36.866.658 | 3,66% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $1.436.115.120 | 24.923.900 | 2,47% | Azioni |
| AMERIPRISE FINANCIAL INC | $1.308.030.705 | 22.705.049 | 2,25% | Azioni |
| Independent Franchise Partners LLP | $1.255.703.498 | 21.792.841 | 2,16% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $938.463.230 | 16.287.109 | 1,61% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $660.776.941 | 11.467.840 | 1,14% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $585.933.423 | 10.168.924 | 1,01% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $581.119.768 | 10.085.383 | 1,00% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494.716.447 | 8.585.846 | 0,85% | Azioni |
| BlackRock, Inc. | $492.399.085 | 8.545.628 | 0,85% | Azioni |
| FMR LLC | $451.250.223 | 7.831.486 | 0,78% | Azioni |
| TWO SIGMA ADVISERS, LP | $446.094.588 | 8.270.200 | 0,77% | Azioni |
| Robeco Institutional Asset Management B.V. | $417.435.581 | 7.244.630 | 0,72% | Azioni |
| GOLDMAN SACHS GROUP INC | $392.167.333 | 6.806.097 | 0,67% | Azioni |
| FIRST TRUST ADVISORS LP | $344.672.508 | 5.981.822 | 0,59% | Azioni |
| Capital International Investors | $340.767.005 | 5.913.752 | 0,59% | Azioni |
| Swiss National Bank | $331.822.056 | 5.758.800 | 0,57% | Azioni |
| VAN ECK ASSOCIATES CORP | $325.076.944 | 5.641.738 | 0,56% | Azioni |
| National Pension Service | $321.412.139 | 5.578.135 | 0,55% | Azioni |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319.229.612 | 5.540.268 | 0,55% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $316.480.270 | 5.492.542 | 0,54% | Azioni |
| Legal & General Group Plc | $315.258.552 | 5.471.339 | 0,54% | Azioni |
| M&G PLC | $306.949.282 | 5.292.229 | 0,53% | Azioni |
| NORDEA INVESTMENT MANAGEMENT AB | $300.773.017 | 5.232.200 | 0,52% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $293.408.012 | 5.092.121 | 0,50% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $288.555.718 | 4.757.720 | 0,50% | Azioni |
| Vanguard Global Advisers, LLC | $270.856.466 | 4.700.737 | 0,47% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $266.201.519 | 4.619.950 | 0,46% | Azioni |
| California Public Employees Retirement System | $263.375.546 | 4.570.905 | 0,45% | Azioni |
| BANK OF AMERICA CORP /DE/ | $263.115.723 | 4.566.396 | 0,45% | Azioni |
| VANGUARD GROUP INC | $247.970.649 | 4.597.157 | 0,43% | Azioni |
| Caisse de depot et placement du Quebec | $243.646.343 | 4.228.503 | 0,42% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $241.222.903 | 4.186.444 | 0,42% | Azioni |
| JANE STREET GROUP, LLC | $224.896.622 | 3.903.100 | 0,39% | Opzione Call |
| WELLINGTON MANAGEMENT GROUP LLP | $214.546.630 | 3.723.475 | 0,37% | Azioni |
| Employees Provident Fund Board | $209.755.987 | 3.640.333 | 0,36% | Azioni |
| CITADEL ADVISORS LLC | $194.502.072 | 3.375.600 | 0,33% | Opzione Put |
| RHUMBLINE ADVISERS | $192.874.042 | 3.347.347 | 0,33% | Azioni |
| LPL Financial LLC | $188.151.217 | 3.265.381 | 0,32% | Azioni |
| BARCLAYS PLC | $186.163.076 | 3.230.876 | 0,32% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185.255.963 | 3.215.133 | 0,32% | Azioni |
| UBS Group AG | $180.243.196 | 3.128.136 | 0,31% | Azioni |
| Qube Research & Technologies Ltd | $178.273.860 | 3.093.958 | 0,31% | Azioni |
| Artemis Investment Management LLP | $175.941.518 | 3.053.480 | 0,30% | Azioni |
| SEB Asset Management AB | $165.520.833 | 2.872.632 | 0,28% | Azioni |
| Ensign Peak Advisors, Inc | $165.119.502 | 2.865.663 | 0,28% | Azioni |
| CITADEL ADVISORS LLC | $157.769.322 | 2.738.100 | 0,27% | Opzione Call |
| JANE STREET GROUP, LLC | $152.525.902 | 2.647.100 | 0,26% | Opzione Put |
| NATIXIS | $145.152.674 | 2.519.137 | 0,25% | Azioni |
| AustralianSuper Pty Ltd | $140.209.857 | 2.433.354 | 0,24% | Azioni |
| Mirae Asset Global Investments Co., Ltd. | $138.044.440 | 2.395.773 | 0,24% | Azioni |
| Bank of New York Mellon Corp | $136.334.163 | 2.366.091 | 0,23% | Azioni |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132.803.901 | 2.304.823 | 0,23% | Azioni |
| PANAGORA ASSET MANAGEMENT INC | $132.622.456 | 2.301.674 | 0,23% | Azioni |
| Capital World Investors | $129.313.224 | 2.244.242 | 0,22% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $129.300.432 | 2.244.020 | 0,22% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125.419.207 | 2.176.661 | 0,22% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $123.353.032 | 2.140.802 | 0,21% | Azioni |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122.879.893 | 2.132.591 | 0,21% | Azioni |
| PFA Pension, Forsikringsaktieselskab | $121.829.832 | 2.114.367 | 0,21% | Azioni |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120.528.714 | 2.234.496 | 0,21% | Azioni |
| MACKENZIE FINANCIAL CORP | $118.944.044 | 2.064.284 | 0,20% | Azioni |
| Pictet Asset Management Holding SA | $116.783.155 | 2.026.687 | 0,20% | Azioni |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116.161.574 | 2.015.994 | 0,20% | Azioni |
| TD Asset Management Inc | $115.669.154 | 2.007.448 | 0,20% | Azioni |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115.240.000 | 2.000.000 | 0,20% | Opzione Call |
| MACQUARIE GROUP LTD | $111.978.478 | 1.943.396 | 0,19% | Azioni |
| Vinva Investment Management Ltd | $109.557.913 | 1.870.866 | 0,19% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $108.509.833 | 1.883.218 | 0,19% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106.751.521 | 1.760.124 | 0,18% | Azioni |
| LMR Partners LLP | $106.066.896 | 1.840.800 | 0,18% | Opzione Put |
| AVIVA PLC | $103.620.639 | 1.798.345 | 0,18% | Azioni |
| PRUDENTIAL FINANCIAL INC | $103.202.606 | 1.791.090 | 0,18% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102.378.000 | 1.776.782 | 0,18% | Azioni |
| STOREBRAND ASSET MANAGEMENT AS | $101.037.131 | 1.753.508 | 0,17% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100.790.172 | 1.749.222 | 0,17% | Azioni |
| BANK OF NOVA SCOTIA | $99.453.647 | 1.726.026 | 0,17% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98.875.920 | 1.716.000 | 0,17% | Azioni |
| KLP KAPITALFORVALTNING AS | $94.673.002 | 1.643.058 | 0,16% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90.576.678 | 1.567.009 | 0,16% | Azioni |
| BANK OF MONTREAL /CAN/ | $89.684.378 | 1.556.480 | 0,15% | Azioni |
| Douglas Lane & Associates, LLC | $89.667.305 | 1.556.184 | 0,15% | Azioni |
| PNC Financial Services Group, Inc. | $89.112.096 | 1.546.548 | 0,15% | Azioni |
| Walleye Trading LLC | $88.014.550 | 1.527.500 | 0,15% | Opzione Call |
| Korea Investment CORP | $86.518.389 | 1.501.534 | 0,15% | Azioni |
| APG Asset Management N.V. | $85.242.422 | 1.691.386 | 0,15% | Azioni |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85.175.958 | 1.478.236 | 0,15% | Azioni |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84.205.059 | 1.764.695 | 0,14% | Azioni |
| Mariner, LLC | $83.309.670 | 1.445.809 | 0,14% | Azioni |
| Retirement Systems of Alabama | $80.928.212 | 1.404.516 | 0,14% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $80.695.542 | 1.400.478 | 0,14% | Azioni |
| Nuveen Asset Management, LLC | $76.733.142 | 1.356.668 | 0,13% | Azioni |
| CWM, LLC | $76.220.909 | 1.256.734 | 0,13% | Azioni |
| Eurizon Capital SGR S.p.A. | $70.986.984 | 1.230.296 | 0,12% | Azioni |
| Aberdeen Group plc | $70.798.674 | 1.228.717 | 0,12% | Azioni |
Insider aziendali 102 insider · 65 dirigenti · 37 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13 Giugno 2025 G | 125.439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 08 Settembre 2006 F | 571.673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 01 Aprile 2026 S | 159.248 | 0 | 3 | $-4.500.496 |
| Jean-Marc Huet | EVP & CFO | 30 Aprile 2009 P | 25.000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 09 Maggio 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10 Marzo 2025 A | 4.711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 02 Marzo 2004 A | 178.889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10 Settembre 2003 A | 60.000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 01 Agosto 2026 M | 24.997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 01 Agosto 2026 M | 13.649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 03 Giugno 2026 F | 12.081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 01 Luglio 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 01 Maggio 2025 J | 12.439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25 Aprile 2025 P | 83.513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 01 Aprile 2025 M | 13.797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10 Marzo 2025 A | 14.967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10 Marzo 2025 A | 5.196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10 Marzo 2025 A | 16.102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10 Marzo 2025 A | 15.839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10 Marzo 2025 A | 364.296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10 Marzo 2024 M | 432.266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24 Agosto 2023 S | 27.868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 01 Luglio 2023 M | 3.453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 03 Maggio 2023 S | 47.751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 02 Maggio 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 01 Aprile 2023 M | 34.734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14 Marzo 2022 S | 16.704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24 Novembre 2021 S | 63.536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30 Luglio 2021 S | 13.777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 03 Giugno 2021 M | 9.485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10 Maggio 2021 S | 31.956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10 Marzo 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10 Marzo 2020 M | 70.946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10 Marzo 2020 M | 137.534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 02 Ottobre 2019 M | 6.214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 03 Aprile 2019 M | 22.223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 01 Agosto 2018 M | 49.424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 06 Settembre 2017 S | 46.297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 03 Settembre 2017 M | 37.974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10 Marzo 2017 A | 20.138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10 Marzo 2017 M | 321.906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13 Marzo 2015 S | 31.015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 01 Luglio 2014 M | 94.374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10 Marzo 2014 A | 4.174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 03 Giugno 2013 M | 148.221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31 Maggio 2013 S | 173.375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 06 Marzo 2012 M | 142.142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 01 Ottobre 2011 M | 43.689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14 Giugno 2011 M | 7.578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13 Maggio 2011 M | 203.170 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 11 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 depositi | 16 Luglio 2020 | — | Deposito iniziale | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27 Febbraio 2019 | — | Deposito iniziale | Investimento passivo | SEC |
| S.S. OR ×3 depositi | 23 Dicembre 2009 | — | Deposito iniziale | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25 Novembre 2009 | — | Deposito iniziale | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 depositi | 27 Febbraio 2009 | — | Deposito iniziale | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 depositi | 08 Ottobre 2008 | — | Deposito iniziale | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 depositi | 06 Giugno 2003 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 16 Aprile 2003 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 03 Febbraio 2003 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 06 Marzo 2002 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 06 Febbraio 2002 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 296 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6,29% | 39.590 NS | 30 Giugno 2026 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1.134.150 SH | 21 Agosto 2026 | Giornaliero |
| ROPE · EA Series Trust | 4,97% | 7.379 NS | 29 Maggio 2026 | N-PORT |
| IHE · iShares Trust | 4,65% | 1.223.984 SH | 21 Agosto 2026 | Giornaliero |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44.768 NS | 30 Aprile 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6.427 NS | 30 Aprile 2026 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3,43% | 4.337.329 NS | 30 Giugno 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101.680 NS | 31 Maggio 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2.332 NS | 30 Aprile 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42.594 NS | 31 Maggio 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48.641.121 NS | 31 Maggio 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,78% | 224.546 SH | 21 Agosto 2026 | Giornaliero |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226.688 NS | 30 Aprile 2026 | N-PORT |
| HDV · iShares Trust | 2,62% | 6.134.190 SH | 21 Agosto 2026 | Giornaliero |
| ACEP · EA Series Trust | 2,52% | 44.211 NS | 29 Maggio 2026 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234.394 NS | 31 Maggio 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210.030 NS | 31 Maggio 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148.728 NS | 31 Maggio 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1.612 NS | 30 Aprile 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,10% | 38.747 SH | 21 Agosto 2026 | Giornaliero |
| HRTS · Tema ETF Trust | 2,09% | 18.939 NS | 31 Maggio 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24.896 NS | 30 Aprile 2026 | N-PORT |
| IYH · iShares Trust | 2,06% | 1.218.183 SH | 21 Agosto 2026 | Giornaliero |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1.086.835 SH | 21 Agosto 2026 | Giornaliero |
| GCOW · Pacer Funds Trust | 2,03% | 1.123.894 NS | 30 Aprile 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6.082.360 NS | 30 Aprile 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15.628 NS | 30 Aprile 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30.055 NS | 30 Aprile 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938.456 NS | 30 Aprile 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1.422 NS | 30 Aprile 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,93% | 31.120 SH | 21 Agosto 2026 | Giornaliero |
| PEY · Invesco Exchange-Traded Fund Trust | 1,83% | 327.924 SH | 21 Agosto 2026 | Giornaliero |
| SDOG · ALPS ETF Trust | 1,83% | 441.820 NS | 31 Maggio 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27.812 NS | 31 Maggio 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,78% | 40.606 NS | 30 Aprile 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8.912 NS | 31 Maggio 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,73% | 6.137.665 SH | 19 Agosto 2026 | Giornaliero |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 213.437 SH | 21 Agosto 2026 | Giornaliero |
| RXL · ProShares Trust | 1,68% | 21.228 NS | 31 Maggio 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26.358 NS | 31 Maggio 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 1,65% | 12.671 NS | 30 Aprile 2026 | N-PORT |
| IXJ · iShares Trust | 1,61% | 1.073.117 SH | 21 Agosto 2026 | Giornaliero |
| NULV · Nushares ETF Trust | 1,57% | 539.514 NS | 30 Aprile 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13.556 NS | 30 Aprile 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11.473 NS | 30 Aprile 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 415.736 SH | 21 Agosto 2026 | Giornaliero |
| COWG · Pacer Funds Trust | 1,47% | 526.151 NS | 30 Aprile 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68.134 NS | 30 Aprile 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21.473 NS | 31 Maggio 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64.178 NS | 30 Aprile 2026 | N-PORT |